The Expression and Significance of Serum MIP-1β and MCP-1in Patients with Rheumatoid Athritis
|Keywords||Rheumatoid arthritis Macrophage inflammatory protein -1β (MIP-1β) Monocyte chemoattractant protein (MCP-1)|
Objective: To detect serum MIP-1β, MCP-1 level, analysis of the differences between the groups with rheumatoid arthritis (Rheumatoid Arthritis RA) disease activity index discussed in RA incidence mechanism of disease and predicting prognosis value. Methods: The study subjects from the First Affiliated Hospital of Suzhou University from July 2010 to December outpatient and hospitalization of 70 RA patients, 20 normal healthy volunteers as a control group. Active RA patients with RA disease activity score (DAS) 28 is divided into group of 35 patients, RA remission phase of 35 cases; imaging X-ray is divided into the group of 22 cases of stage Ⅰ 26 cases, Ⅱ, Ⅲ of group 17 cases, Ⅳ of five cases. Serum MIP-1β, MCP-1 levels were detected, the simultaneous detection of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), anti-cyclic citrullinated peptide antibody (CCP) and record the duration of morning stiffness , tender joint count, swollen joint count, health questionnaire survey (HAQ), pain scale (VAS) activity index and disease progression. Comparison among the groups serum MIP-1β, MCP-1 level, and analyze their differences and correlation with the indicators. Serum MIP-1β, MCP-1 detection using enzyme-linked immunosorbent assay (ELISA) to complete the RF and anti-CCP antibodies were measured by ELISA. Results: (1) serum level of MIP-1β RA group was significantly higher than the normal healthy control group, and the active phase was significantly higher than in remission group, the difference was statistically significant (P lt; 0.01). (2) serum MCP-1 levels in RA group was significantly higher than the normal healthy group, the difference was statistically significant (P lt; 0.01), imaging grade Ⅰ, Ⅱ, Ⅲ, Ⅳ period serum MCP-1 levels progressively elevated, and Ⅳ group MCP-1 levels were significantly higher than Ⅰ, II, III phase group, the difference was statistically significant (P lt; 0.01), but SNK method twenty-two comparison Ⅰ, Ⅱ, Ⅲ stage group No statistically significant difference (P gt; 0.05). (3) The serum level of MIP-1β and duration of morning stiffness, ESR, CRP, swollen joint count, tender joint count, HAQ, VAS, DAS28 was integral positively correlated with disease activity index (P lt; 0.05); and judgment with RA disease indicators of RF and anti-CCP antibody positive correlation (r = 0.471,0.421, p lt; 0.05). (4) serum levels of MCP-1 section malformation group than in the the joint deformity group, the difference was statistically significant (P lt; 0.05). No statistically significant difference between (5) serum of MIP-1β level imaging classification group, serum MCP-1 levels in active phase and remission phase group difference was not statistically significance (P gt; 0.05); Serum MIP-1β, and MCP- 1 no correlation (r = 0.266, P gt; 0.05), but they are nothing to do with age, gender, disease duration. Conclusion: Serum MIP-1β, MCP-1 may be involved in RA occurs, the development of the pathophysiological process; MIP-1β with RA disease activity can be used as one of the indicators of the judgment RA disease activity; MCP-1 and RA joint undermine the relationship, both involved in the pathogenesis of RA, no significant correlation.